FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

(2021) P. Schmid et al.   ANNALS OF ONCOLOGY

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

(2021) N. Harbeck et al.   ANNALS OF ONCOLOGY

U.S. FDA Drug Approvals for Breast Cancer — A Decade in Review

(2021) Shaily Arora et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer

(2020) Suparna Wedam et al.   CLINICAL CANCER RESEARCH

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

(2020) Stephen R. D. Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer

(2019) Peter A. Fasching et al.   BREAST CANCER RESEARCH AND TREATMENT

U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer

(2018) Harpreet Singh et al.   CLINICAL CANCER RESEARCH

FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer

(2018) Lynn J. Howie et al.   CLINICAL CANCER RESEARCH

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY